Arginine Hydrochloride (Phebra) is a medicine containing the active ingredient(s) arginine hydrochloride. On this page you will find out more about Arginine Hydrochloride (Phebra), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.
Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.
Active ingredient in this medicine: arginine hydrochloride
Information for medicine and pack size:
Arginine Hydrochloride (Phebra) 60% (15 g/25 mL) concentrated injection, 10 x 25 mL vials
Consumer Medicine Information leaflet:
This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.
What this medicine is for
INDICATIONS AS AT 01 JAN 1991 : Arginine stimulates the release of growth hormone by the pituitary gland and may be used instead of , or in addition to, other tests such as insulin-induced hypoglycaemia, for the evaluation of growth disorders; false positive and false negative results are relatively common and evaluation therefore should not be made on the basis of a single arginine test. Arginine is used as an acidifying agent in severe metabolic alkalosis. Arginine is used in some conditions accompanied by hyperammonaemia stemming from inborn errors of the urea cycle, particularly where there is a severe deficiency of ornithine carbamoyl transferase or carbamoyl phosphate synthetase where respiratory alkalosis is present.
Table of characteristics
|Visual appearance||Clear colourless solution|
|Dosage Form||Injection, intravenous infusion|
|Route of administration||Intravenous|
25mL x 10: Not scheduled. Not considered by committee
There is one type of pack available.
Pack type 1
|Storage temperature||Store below 30 degrees Celsius|
|Storage conditions||No information available|
|Life time||3 Years|
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information
The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.
Is this medication banned in sport?
Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.